Physician profile
Ruby Hanna
NPI 1750502811
$9,584.15
in general payments reported to CMS, 2019-2025
69 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $712 · 2021: $1,245 · 2022: $1,512 · 2023: $1,769 · 2024: $1,796 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,605 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,605.07 |
| Education | $372.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $818.22 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $634.50 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $587.47 | 2019-2025 | Imbruvica, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $524.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $496.08 | 2020-2025 | Enhertu, Vanflyta, Injectafer |
| Incyte Corporation | $491.42 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $444.79 | 2019-2024 | |
| Celgene Corporation | $376.86 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $329.66 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $298.88 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $295.77 | 2020-2025 | Xpovio |
| Glaxosmithkline, LLC. | $287.07 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $284.59 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $257.35 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Abbvie INC. | $257.35 | 2021-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.